Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation

被引:64
作者
Salazar, R
Solá, C
Maroto, P
Tabernero, JM
Brunet, J
Verger, G
Valentí, V
Cancelas, JA
Ojeda, B
Mendoza, L
Rodríguez, M
Montesinos, J
López-López, JJ
机构
[1] Univ Autonoma Barcelona, Hosp Santa Cruz & San Pablo, Dept Med Oncol, E-08025 Barcelona, Spain
[2] Univ Autonoma Barcelona, Hosp Santa Cruz & San Pablo, Infect Dis Unit, E-08025 Barcelona, Spain
[3] Canc Res Inst, Barcelona, Spain
关键词
bacteremia; fever; high-dose chemotherapy; imipenem; infectious complications; PBSC transplantation;
D O I
10.1038/sj.bmt.1701520
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC, They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery, Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively, Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred, Grampositive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis, Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one, The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 51 条
[21]   GRANULOCYTE-COLONY-STIMULATING FACTOR ACCELERATES NEUTROPHIL ENGRAFTMENT FOLLOWING PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION - A PROSPECTIVE, RANDOMIZED TRIAL [J].
KLUMPP, TR ;
MANGAN, KF ;
GOLDBERG, SL ;
PEARLMAN, ES ;
MACDONALD, JS .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1323-1327
[22]   PROPHYLAXIS OF BACTERIAL-INFECTIONS WITH CIPROFLOXACIN IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
LEW, MA ;
KEHOE, K ;
RITZ, J ;
ANTMAN, KH ;
NADLER, L ;
TAKVORIAN, T ;
MAYER, R ;
KALISH, L ;
FINBERG, R .
TRANSPLANTATION, 1991, 51 (03) :630-636
[23]  
LINCH DC, 1993, BONE MARROW TRANSPL, V11, P307
[24]   PROGRESS IN THE DIAGNOSIS AND MANAGEMENT OF ASPERGILLOSIS IN BONE-MARROW TRANSPLANTATION - 13 YEARS EXPERIENCE [J].
MCWHINNEY, PHM ;
KIBBLER, CC ;
HAMON, MD ;
SMITH, OP ;
GANDHI, L ;
BERGER, LA ;
WALESBY, RK ;
HOFFBRAND, AV ;
PRENTICE, HG .
CLINICAL INFECTIOUS DISEASES, 1993, 17 (03) :397-404
[25]  
MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
[26]  
2-6
[27]  
Mossad SB, 1996, BONE MARROW TRANSPL, V18, P265
[28]  
MOTZER RJ, 1992, CANCER-AM CANCER SOC, V69, P550, DOI 10.1002/1097-0142(19920115)69:2<550::AID-CNCR2820690245>3.0.CO
[29]  
2-D
[30]  
Nosanchuk JD, 1996, BONE MARROW TRANSPL, V18, P355